



03-13-06
PCT/PTO 10 MAR 2006
EXPRESS MAIL NO.: EV452776997US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Muller et al.

Confirmation No.: 9094

Application No.: 10/535,004

Group Art Unit: To Be Assigned

Filed: May 11, 2005

Examiner: To Be Assigned

For: METHODS OF USING AND
COMPOSITIONS COMPRISING (+)-
3-(3,4-DIMETHOXY-PHENYL)-3-(1-
OXO-1,3-DIHYDRO-ISOINDOL-2-
YL)-PROPIONAMIDE

Attorney Docket No.: 9516-058-999
(CAM No.: 501872-999057)

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references **C11-C18** listed on the attached Substitute for Form PTO 1449 entitled "Information Disclosure Statement By Applicant." Copies of references **C11-C18** are provided herewith. This Information Disclosure Statement supplements the Information Disclosure Statement filed on August 31, 2005.


Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of a first Office action on the merits. Therefore, no fee is believed to be due.

Should any fee be required, however, please charge such fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: March 10, 2006



Yeahsil Moon (Reg. No.)
For: Anthony M. Insogna 52,042
35,203
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosures

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 9516-058-999 (CAM No. 501872-999057)	APPLICATION NO. 10/535,004
	APPLICANT: Muller et al.	
	FILING DATE: May 11, 2005	ART UNIT: CONF. NO.: TBA 9094

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*		DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01				
	A02				
	A03				
	A04				
	A05				
	A06				

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
	B01						
	B02						
	B03						
	B04						

EXAMINER'S INITIALS*	NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)						
	C11	DREDGE et al., 2003, "Angiogenesis inhibitors in cancer therapy," Curr. Opin. Investig. Drugs 4(6):667-673					
	C12	DREDGE et al., 2002, "Immunological effects of thalidomide and its chemical and functional analogs," Crit. Rev. Immunol. 22(5-6):425-437					
	C13	DREDGE et al., 2002, "Recent developments in antiangiogenic therapy," Expert Opin. Biol. Ther. 2(8):953-966					
	C14	GEE et al., 2003, "Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition," Cancer Res. 63(23):8073-8078					
	C15	MARRIOTT et al., 2001, "Immunotherapeutic and antitumour potential of thalidomide analogues," Expert Opin. Biol. Ther. 1(4):1-8					
	C16	MARRIOTT et al., 2002, "Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells," Clin. Exp. Immunol. 130(1):75-84					
	C17	MOLOSTVOV et al., 2004, "The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures," Br. J. Haematol. 124(3):366-375					
	C18	MULLER et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," Bioorg. Med. Chem. Lett. 9(11):1625-1630					

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.